ClinicalTrials.gg
CompletedNCT06557603Updated Aug 20, 2024

Bioequivalence Study of Ivermectin 1% Cream and Soolantra (Ivermectin) 10 mg/g Cream

A Phase 1 interventional study of Ivermectin cream and Soolantra ® (Ivermectin) cream in Rosacea, sponsored by Humanis Saglık Anonim Sirketi. Completed at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-20.

Sponsored by Humanis Saglık Anonim Sirketi · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Mar 2024, registered Aug 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ivermectin in Rosacea — none open to participants now, none under way, none of them phase 3. Ivermectin · Rosacea.

Enrollment
9th of 11
44 · median 486
Started
2024
the only one that year
Phase 1
2 of 11
none open now
Registered
10th of 11
by date
Lead sponsor
1 of 11
Humanis Saglık Anonim Sirketi

Among the 11 studies testing ivermectin in Rosacea, this one is the 9th largest by enrollment, is the only one that started in 2024, is one of 2 in phase 1, and was the 10th registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 11 studies testing ivermectin in Rosacea is open now. The open studies under Rosacea, anywhere →

About ivermectin

Ivermectin: first FDA approval 1996 (STROMECTOL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing ivermectin in Rosacea as a file.
02

Study summary

Single dose bioequivalence study of Ivermectin 1% cream and Soolantra (Ivermectin) 10 mg/g cream in healthy adult human subjects.

Read the detailed description

An open label, randomized, four-period, two treatment, two-sequence, fully replicate, crossover, balanced, single dose bioequivalence study.

03

Conditions studied

  • Rosacea

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18 to 45 years old, both inclusive.
  • Gender: Male and/or non-pregnant, non-lactating female. A. Female of had a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test performed within 28 days prior to first cream application day. They has used an acceptable form of .

B. For female of childbearing potential, acceptable forms of contraception included the following:

i. Non hormonal intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or ii. Barrier methods containing or used in conjunction with a spermicidal agent, or iii. Surgical sterilization or iv. Practicing sexual abstinence throughout the course of the study.

C. Female was not considered of childbearing potential if one of the following was reported and documented on the medical history:

i. with spontaneous amenorrhea for at least one year, or ii. Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or iii. Total hysterectomy and an absence of bleeding for at least 3 months.

  • : 18.5 to 30.0 kg/m2, both inclusive; BMI value were rounded off to one significant digit after decimal point (e.g. 30.04 rounded down to 30.0, while 18.45 rounded up to 18.5).
  • Volunteer having weight ≥ 50 Kg.
  • The Volunteers were able to communicate effectively with study personnel.
  • The Volunteers willing to provide written to participate in the study.
  • All volunteers were judged by the principal or sub-investigator or physician as normal and healthy during a pre-study safety assessment performed within 28 days of the first dose of cream application which included:

    1. A physical examination (clinical examination) with no finding.

Exclusion criteria

Exclusion Criteria:

Volunteers who met any one of the following criteria were not enrolled in the study.

  • History of allergic responses to Ivermectin or other related drugs, or any of its formulation ingredients.
  • Female subjects of had unprotected sexual intercourse with any non-sterile male partner (i.e. male who was not sterilized by vasectomy for at least 6 months) within 14 days prior to the first dose of cream application.
  • Currently pregnant, lactating or breast-feeding (for female volunteers).
  • Use of oral within 30 days prior to the first dose of cream application (for female volunteers).
  • Had significant diseases or abnormal findings during screening [medical history, physical examination (clinical examination), laboratory evaluations, recording, gynecological history and examination (including pelvic examination and routine breast examination) (for female volunteers)].
  • Any disease or condition like diabetes, psychosis or others, which compromised the haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system or any other body system.
  • History or presence of bronchial asthma.
  • Use of any hormone replacement therapy within 3 months prior to the first dose of cream application.
  • A depot injection or implant of any drug within 3 months prior to the first dose of cream application.
  • Use of CYP enzyme inhibitors or inducers within 30 days prior to the first dose of cream application.
  • History or evidence of drug dependence or of alcoholism or of moderate alcohol use.
  • Smokers who smoked 10 or more cigarettes per day or 20 or more biddies per day or those who could not refrained from smoking during the study period.
  • History of difficulty with donating blood or difficulty in accessibility of veins.
  • A positive hepatitis screen (includes subtypes B \& C).
  • A positive test result for antibody.
  • Volunteers who had received a known drug within seven elimination half life of the administered drug prior to the first dose of cream application.
  • Volunteers who had donated blood or loss of blood 50 ml to 100 ml within 30 days or 101 ml to 200 ml within 60 days or >200 ml within 90 days (excluding volume drawn at screening for this study) prior to first dose of cream application, whichever was greater.
  • Sitting systolic blood pressure less than 100 mmHg or greater than 140 mmHg or sitting diastolic blood pressure less than 60 mmHg or greater than 90 mmHg and pulse rate less than 60 or greater than 100 beats per minute during screening.
  • Illness within 14 days before the start of the study.
  • Hospitalisation within 3 months before the start of the study (at the discretion of the Investigator).
  • Intolerance to venipuncture.
  • Any food allergy, intolerance, restriction or special diet that, in the opinion of the principal investigator or sub-investigator, the volunteer's participation in this study.
  • Institutionalized volunteers.
  • Use of any prescribed medications within 14 days prior to the first dose of cream application.
  • Use of any OTC products, vitamin and herbal products, etc., within 7 days prior to the first dose of cream application.
  • Use of grapefruit and grapefruit containing products within 7 days prior to the first dose of cream application.
  • Ingestion of any caffeine or xanthine products (i.e. coffee, tea, chocolate, and caffeinecontaining sodas, colas, etc.), cigarettes and tobacco containing products, recreational drugs, alcohol or other alcohol containing products within 48 hours prior to the first dose of cream application.
  • Ingestion of any unusual diet, for whatever reason (e.g.: low sodium) for three weeks prior to the first dose of cream application.
  • Volunteer has tattoo, mark of injury/surgery, any discolouration of skin, any ongoing skin disease or history of frequent skin disease, damaged skin at application sites or has cracks/hardening/scarring at the application site.
  • Presence of open sores, or other skin abnormalities at the application site.
  • History of cryodestruction or chemodestruction, dermabrasion, photodynamic therapy, intralesional within one month.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Ivermectin cream

    Ivermectin 1% cream

    Drug: Ivermectin cream · Drug: Soolantra ® (Ivermectin) cream

  • Active comparator
    Soolantra (Ivermectin) cream

    Soolantra (Ivermectin) 10 mg/g cream

    Drug: Ivermectin cream · Drug: Soolantra ® (Ivermectin) cream

Interventions

  • \[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).

  • \[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).

06

What researchers measure

Primary outcomes

  1. Maximum measured plasma concentration (Cmax)

    If the reference product intra-subject CV is less than or equal to 30% for Cmax, then the 90% confidence interval of the relative mean Cmax of the test to reference formulation for Ln-transformed data was to be within 80.00% to 125.00%.

    Time frame: 21 hours

  2. Area under the plasma concentration versus time curve from the time zero time point to the last quantifiable concentration (AUCt)

    The 90% confidence interval of the relative mean (Geometric mean) of the Test to reference formulation for Ln-transformed AUCt was to be within 80.00% to 125.00%

    Time frame: 21 hours

Secondary outcomes

  1. Area under the plasma concentration versus time curve from time zero to infinity (AUCi)

    Descriptive statistic

    Time frame: 21 hours

  2. Time of the maximum measured plasma concentration (Tmax)

    Descriptive statistic

    Time frame: 21 hours

07

Study locations

1 site
  • Cliantha Research Limited
    Vadodara, Gujarat 390012, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Jul 2024, 4 months.

Of 13 phase 1 interventional studies under Rosacea, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2024
First posted
Aug 16, 2024
StartActual
Mar 6, 2024
Primary completionActual
Jul 11, 2024
CompletionActual
Jul 22, 2024
Last update
Aug 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06557603
Responsible party
Sponsor
First posted
Aug 16, 2024
Start date
Mar 6, 2024
Primary completion
Jul 11, 2024
Completion
Jul 22, 2024
Last update
Aug 20, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivermectin

Start the discussion